Cabozantinib is a multi-kinase inhibitor that gives oncologists an oral, targeted-therapy option across three genuinely distinct cancer types treated by the same drug — kidney, liver, and thyroid cancer — which makes it a versatile addition for hospitals managing patients across multiple oncology sub-specialties rather than a single-indication product.
- Approved indications: Renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), differentiated thyroid cancer
- Mechanism: Inhibits multiple tyrosine kinases (including MET, VEGFR2, and RET) simultaneously, blocking several tumor-growth and blood-vessel-formation pathways at once
- Administration: Oral tablet, once daily
- Oral advantage: Provides a targeted-therapy alternative to the injectable oncology biologics in our catalogue treating the same cancer types, relevant for distributors serving facilities without infusion infrastructure
- Hemorrhage risk: Significant bleeding risk requires careful patient selection and monitoring, particularly in patients with a bleeding history
- GI perforation risk: A rare but serious risk requiring immediate medical attention if abdominal symptoms develop
- Hypertension: Common and requires regular blood pressure monitoring
- Wound-healing complications: Treatment should be held before and after any planned surgery, similar to the precaution with Bevacizumab
- Hepatotoxicity: Regular liver function monitoring recommended
- Pregnancy: Contraindicated
- Certification: WHO-GMP tablet manufacturing
- Batch-specific testing: Dissolution and bioequivalence testing per batch
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: Standard export logistics, no cold chain required
- Coverage: Global export markets
- Tracking: Full shipment tracking included
- Institutional buyers: Hospital and pharmacy distributor support across kidney, liver, and thyroid cancer treatment programs
- Unregistered markets: Named-patient supply pathway available
What is Cabozantinib used for?
Treats kidney cancer, liver cancer, and differentiated thyroid cancer.
Get Cabozantinib price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Is it chemotherapy?
No, it's a targeted oral therapy that blocks multiple cancer-growth pathways simultaneously.
Does it need to be stopped before surgery?
Yes, similar to other anti-angiogenic drugs, it should be held before and after any planned surgery due to wound-healing risk.
Who supplies Cabozantinib from India?
WHO-GMP certified tablet manufacturing with full export documentation.
